Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- HPE +15.3%, SFIX +13.5%, CRWD +11.5%, GWRE +8.7%, VRNT +8.3%, LE +5.3%, UNFI +4%, OLLI +3% (also announces exec transition plan), REVG +2.5%, CPB +1.4%
Other news:
- WKME +41.7% (WalkMe Ltd. to be acquired by SAP for $14.00 per share)
- CLLS +19.5% (EC grants Orphan Drug Designation for UCART22)
- DDD +16.8% (expands into digital dentistry market; also announces large $250 mln contract for clear aligners)
- ACET +13.2% (FDA has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis) VIR +7.1% (Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment)
- ABUS +6.6% (Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure)
- AMBC +4.5% (Ambac to sell its legacy financial guarantee businesses to funds managed by Oaktree Capital Management (OAK) for $420 mln in cash; to acquire majority stake in Beat Capital Partners)
- ESTA +4.3% (provides Center for Devices and Radiological Health update; inspection by the FDA has been rescheduled to take place within the next thirty days)
- ALT +3.3% (Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis)
- APO +3% (APO funds to pay Intel $11 bln to acquire 49% interest in JV related to Intel's Fab 34 in Ireland)
- DENN +3% (entered into a pre-arranged stock trading plan for the purpose of repurchasing a limited number of shares of the Company's common stock)
- TCOM +1.4% (prices offering of $1.3 billion of convertible senior notes due 2029)
- CWCO +1.1% (announces settlement of dispute with Mexico)
- MNKD +1.1% ( Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions)
- IMAB +1.1% (Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers)
Analyst comments:
- AMAT +2.3% (upgraded to Equal Weight from Underweight at Barclays)
- KLAC +1.9% (upgraded to Equal Weight from Underweight at Barclays)
- SAM +1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)